The Safety and Efficacy of Universal CAR-T Cells Targeting BCMA in the Treatment of Refractory NMOSD

NCT06633042 · clinicaltrials.gov ↗

PHASE1

Phase

NOT_YET_RECRUITING

Status

18

Enrollment

INDUSTRY

Sponsor class

Conditions

Autoimmune Disease

Interventions

DRUG: Universal BCMA-CD19 CART

Sponsor

Bioray Laboratories

Collaborators

[object Object]